Company news
Whitehawk Therapeutics, Inc. news in 2026
Whitehawk Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
October 1, 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
September 12, 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
September 10, 2026
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
July 6, 2026
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
May 30, 2026
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
May 28, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
May 21, 2026
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
May 20, 2026
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 15, 2026
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
May 13, 2026
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 7, 2026
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
April 19, 2026
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
April 16, 2026
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
April 10, 2026
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 16, 2026
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
March 11, 2026
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
January 8, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 36 slides · August 2026